iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Serum Institute of India acquires 20% stake in IntegriMedical

18 May 2024 , 12:21 AM

The largest vaccine manufacturer in the world, Serum Institute of India (SII), purchased a 20% share in IntegriMedical, a US-based company, in order to further the development of needle-free injection system technology.

The deal’s financial specifics were kept under wraps.

In a statement released on Friday, Pune-based SII said that the collaboration with IntegriMedical is in line with both company’s goals of “Health for All” and “Transforming Healthcare Globally” through the provision of patient comfort, assurance of improved patient compliance, a decrease in needle-stick injuries, and an improvement in the effectiveness of liquid medication through needle-free dispersion.

IntegriMedical has created a needle-free injection system (N-FIS) that is patented in the US and uses mechanical power to create high-velocity jet streams for the administration of medications and biologics.

SII claims that N-FIS will soon be offered on the private Indian market.

“At SII, we’re always looking for ways to invest in technology that support our goal of enabling universal access to inexpensive healthcare. The Needle-Free Injection Systems (N-FIS) from IntegriMedical mark a substantial breakthrough in medication delivery, and we hope to provide vaccinations without the need for needles.” According to Adar Poonawalla, CEO of SII, “We think this could potentially revolutionise the way we administer vaccines, making the process more comfortable for patients and healthcare professionals.”

The goal of SII and IntegriMedical’s partnership is to combine their strengths in vaccine production, cutting-edge medication delivery technologies, and strong research backgrounds.

The announcement read, “Together, the companies aim to expand access to care and improve efficiencies in the global healthcare industry.”

The investment by SII, according to IntegriMedical’s MD Sarvesh Mutha, is evidence of the company’s N-FIS technology’s promise to transform medicine delivery.

“We will find great value in SII’s vaccine manufacturing and global distribution experience as we strive to increase patient access to our technology on a global scale,” he stated.

For feedback and suggestions, write to us at editorial@iifl.com

For opening a demat account click on: https://www.indiainfoline.com/

For doing stock trading & investments, go to: https://ttweb.indiainfoline.com/trade/Login.aspx

For loans, go to: https://www.iifl.com/

Related Tags

  • IntegriMedical
  • Serum Institute of India
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Most Read News

Indices end lower
21 Jun 2024|03:40 PM
Market Update: Nifty and Sensex Dip
21 Jun 2024|01:47 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.